Local news WXIII 12 reports that Wake Forest University is at the forefront of clinical research trial targeting multiple myeloma, the second most common blood cancer in the U.S., with BiTE therapy. With this therapy, an antibody when infused takes the immune system cells (T-cells) and takes them by the hand and leads it to the cancer cell to destroy it.
BiTE is a registered trademark of MICROMET AG. Which was acquired by large biotech major Amgen. A review of Wake Forest’s Multiple Myeloma website reveals more about the BiTE trial—as one of the clinical trial options for treatment. It reports that clinical trials that give access to new treatments that may benefit patients with myeloma. These may include immune therapy, CAR-T therapy, BiTE therapy, vaccines or new chemotherapy agents.
The Wake Forest Comprehensive Cancer Center lists many clinical trials of which three focus on Multiple Myeloma. We were not able to identify the exact trial in Clinicaltrials.gov however we do know the lead investigator listed below.
Lead Research/InvestigatorSource: WXIII 12